Lymphatic vessel activation in cancer

Annals of the New York Academy of Sciences

Volumn 1131, Issue , 2008, Pages 235-241

  Das, Suvendu ^a   Skobe, Mihaela ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Lymphangiogenesis; Lymphatic endothelium; Lymphatic metastasis; Sentinel lymph node biopsy; VEGF; VEGFR

Indexed keywords

VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

CONFERENCE PAPER; HUMAN; INFLAMMATION; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; METASTASIS; NEOPLASM; NONHUMAN;

EID: 44449109524     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1413.021     Document Type: Conference Paper

References (81)

1. Rayter, Z. 2003. Medical Therapy of Breast Cancer. Cambridge University Press. Cambridge, UK.
2. Tanis, P.J. et al. 2001. History of sentinel node and validation of the technique. Breast Cancer Res. 3 : 109 112.
3. Morton, D.L. et al. 1992. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 127 : 392 399.
4. Cochran, A.J. et al. 2000. The Augsburg Consensus : techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 89 : 236 241.
5. Morton, D.L. et al. 2006. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355 : 1307 1317.
6. Wu, C.W. et al. 2006. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 7 : 309 315.
7. Ricciardi, R. & N.N. Baxter. 2007. Association versus causation versus quality improvement: setting benchmarks for lymph node evaluation in colon cancer. J. Natl. Cancer Inst. 99 : 414 415.
8. Swanson, G.P., I.M. Thompson & J. Basler. 2006. Current status of lymph node-positive prostate cancer: incidence and predictors of outcome. Cancer 107 : 439 450.
9. Balch, C.M. 1988. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J. Clin. Oncol. 6 : 163 172.
10. Bembenek, A.E. et al. 2007. Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial. Ann. Surg. 245 : 858 863.
11. Hartgrink, H.H. et al. 2004. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J. Clin. Oncol. 22 : 2069 2077.
12. Truong, P.T. et al. 2002. Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-ST2 breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 54 : 794 803.
13. Joslyn, S.A. & B.R. Konety. 2005. Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Res. Treat. 91 : 11 18.
14. Kashani-Sabet, M. et al. 2001. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch. Dermatol. 137 : 1169 1173.
15. Straume, O. & L.A. Akslen. 1996. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer 78 : 1211 1219.
16. Hoda, S.A. et al. 2006. Issues relating to lymphovascular invasion in breast carcinoma. Adv. Anat. Pathol. 13 : 308 315.
17. Kiruparan, P. & L. Forrest. 2007. Prediction in breast cancer of the extent of axillary node involvement from the size and lymphovascular invasion status of the primary tumour: medico-legal considerations. Eur. J. Surg. Oncol. 33 : 435 437.
18. Lee, C.C. et al. 2007. Survival predictors in patients with node-negative gastric carcinoma. J. Gastroenterol. Hepatol. 22 : 1014 1018.
19. Dicken, B.J. et al. 2006. Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann. Surg. 243 : 64 73.
20. Quek, M.L. et al. 2005. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J. Urol. 174 : 103 106.
21. Cheng, L. et al. 2005. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J. Urol. 174 : 2181 2185.
22. Kim, J.C. et al. 2005. Genetic and pathologic changes associated with lymphovascular invasion of colorectal adenocarcinoma. Clin. Exp. Metastasis 22 : 421 428.
23. Benson, R. et al. 2001. Local excision and postoperative radiotherapy for distal rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 50 : 1309 1316.
24. Hachisuga, T. et al. 1999. The grading of lymphovascular space invasion in endometrial carcinoma. Cancer 86 : 2090 2097.
25. Lotan, Y. et al. 2005. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J. Clin. Oncol. 23 : 6533 6539.
26. May, M. et al. 2007. Prognostic impact of lymphovascular invasion in radical prostatectomy specimens. BJU Int. 99 : 539 544.
27. Lee, A.H. et al. 2006. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur. J. Cancer 42 : 357 362.
28. Van Der Auwera, I. et al. 2006. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br. J. Cancer 95 : 1611 1625.
29. Pepper, M.S. et al. 2003. Lymphangiogenesis and tumor metastasis. Cell Tissue Res. 314 : 167 177.
30. Swartz, M.A. & M. Skobe. 2001. Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc. Res. Tech. 55 : 92 99.
31. Cassella, M. & M. Skobe. 2002. Lymphatic vessel activation in cancer. Ann. N.Y. Acad. Sci. 979 : 120 130.
32. Isaka, N. et al. 2004. Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res. 64 : 4400 4404.
33. Hartveit, E. 1990. Attenuated cells in breast stroma: the missing lymphatic system of the breast. Histopathology 16 : 533 543.
34. Carmeliet, P. & R.K. Jain. 2000. Angiogenesis in cancer and other diseases. Nature 407 : 249 257.
35. Padera, T.P. et al. 2002. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296 : 1883 1886.
36. Achen, M.G. et al. 1998. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA 95 : 548 553.
37. Joukov, V. et al. 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15 : 290 298.
38. Lee, J. et al. 1996. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. USA 93 : 1988 1992.
39. Joukov, V. et al. 1997. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16 : 3898 3911.
40. Karkkainen, M.J. et al. 2001. A model for gene therapy of human hereditary lymphedema. Proc. Natl. Acad. Sci. USA 98 : 12677 12682.
41. Yuan, L. et al. 2002. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129 : 4797 4806.
42. Skobe, M. et al. 2001. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7 : 192 198.
43. Stacker, S.A. et al. 2001. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7 : 186 191.
44. Mandriota, S.J. et al. 2001. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20 : 672 682.
45. Karpanen, T. et al. 2001. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61 : 1786 1790.
46. He, Y. et al. 2002. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 94 : 819 825.
47. Yanai, Y. et al. 2001. Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in mice. J. Exp. Clin. Cancer Res. 20 : 419 428.
48. Kopfstein, L. et al. 2007. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am. J. Pathol. 170 : 1348 1361.
49. Krishnan, J. et al. 2003. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res. 63 : 713 722.
50. Hoshida, T. et al. 2006. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res. 66 : 8065 8075.
51. Harrell, M.I., B.M. Iritani & A. Ruddell. 2007. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am. J. Pathol. 170 : 774 786.
52. Enholm, B. et al. 1997. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14 : 2475 2483.
53. Li, J. et al. 2005. Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. Oncogene 24 : 5510 5520.
54. Tang, Y. et al. 2003. Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res. 63 : 1166 1171.
55. Su, J.L. et al. 2004. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res. 64 : 554 564.
56. Crnic, I. et al. 2004. Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis. Cancer Res. 64 : 8630 8638.
57. Kerjaschki, D. 2005. The crucial role of macrophages in lymphangiogenesis. J. Clin. Invest. 115 : 2316 2319.
58. Schoppmann, S.F. et al. 2002. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 161 : 947 956.
59. Iwata, C. et al. 2007. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res. 67 : 10181 10189.
60. Schoppmann, S.F. et al. 2006. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 139 : 839 846.
61. Skobe, M. et al. 2001. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am. J. Pathol. 159 : 893 903.
62. Cao, Y. 2005. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat. Rev. Cancer 5 : 735 743.
63. Hirakawa, S. et al. 2005. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J. Exp. Med. 201 : 1089 1099.
64. Hirakawa, S. et al. 2007. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109 : 1010 1017.
65. Qian, C.N. et al. 2006. Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res. 66 : 10365 10376.
66. Ruddell, A. et al. 2007. p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis. Oncogene [Epub ahead of print].
67. Van Den Eynden, G.G. et al. 2006. Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. Br. J. Cancer 95 : 1362 1366.
68. Van Den Eynden, G.G. et al. 2007. Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. Clin. Cancer Res. 13 : 5391 5397.
69. Angeli, V. et al. 2006. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 24 : 203 215.
70. Podgrabinska, S. et al. 2002. Molecular characterization of lymphatic endothelial cells. Proc. Natl. Acad. Sci. USA 99 : 16069 10674.
71. Petrova, T.V. et al. 2002. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J. 21 : 4593 4599.
72. Irjala, H. et al. 2001. Mannose receptor is a novel ligand for L-selectin and mediates lymphocyte binding to lymphatic endothelium. J. Exp. Med. 194 : 1033 1042.
73. Irjala, H. et al. 2003. The same endothelial receptor controls lymphocyte traffic both in vascular and lymphatic vessels. Eur. J. Immunol. 33 : 815 824.
74. Irjala, H. et al. 2003. Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res. 63 : 4671 4676.
75. Shields, J.D. et al. 2007. Chemokine-mediated migration of melanoma cells towards lymphatics - a mechanism contributing to metastasis. Oncogene 26 : 2997 3005.
76. Wiley, H.E. et al. 2001. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl. Cancer Inst. 93 : 1638 1643.
77. Kriehuber, E. et al. 2001. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J. Exp. Med. 194 : 797 808.
78. Szuba, A. et al. 2002. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J. 16 : 1985 1987.
79. Nibbs, R.J. et al. 2001. The beta-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am. J. Pathol. 158 : 867 877.
80. Jamieson, T. et al. 2005. The chemokine receptor D6 limits the inflammatory response in vivo. Nat. Immunol. 6 : 403 411.
81. Nibbs, R.J. et al. 2007. The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J. Clin. Invest. 117 : 1884 1892.